ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) disclosed that it repurchased 58,200 H-shares on 24 July 2026 through on-market transactions on the Hong Kong Stock Exchange at prices between HKD 3.17 and HKD 3.31 per share. The volume-weighted average repurchase price was approximately HKD 3.23, bringing the total cash outlay to HKD 0.19 million.

Following the transaction, treasury shares increased from 1.96 million to 2.02 million, while issued shares outstanding (excluding treasury shares) fell marginally by 0.0139% to 418.46 million. Total issued shares remained 420.48 million.

The buyback forms part of the mandate approved by shareholders on 28 May 2026, which authorises the repurchase of up to 43.15 million shares. Cumulative repurchases under this mandate now stand at 2.02 million shares, equivalent to 0.47% of the company’s issued share capital as at the mandate date.

In line with Hong Kong listing rules, ImmuneOnco is subject to a 30-day moratorium on new share issues or sales of treasury shares, effective until 23 August 2026.